(NASDAQ: BFRI) Biofrontera's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.
Biofrontera's earnings in 2025 is -$11,525,000.On average, 1 Wall Street analyst forecast BFRI's earnings for 2025 to be -$9,162,811, with the lowest BFRI earnings forecast at -$9,162,811, and the highest BFRI earnings forecast at -$9,162,811. On average, 1 Wall Street analyst forecast BFRI's earnings for 2026 to be $1,605,853, with the lowest BFRI earnings forecast at $1,605,853, and the highest BFRI earnings forecast at $1,605,853.
In 2027, BFRI is forecast to generate $3,778,479 in earnings, with the lowest earnings forecast at $3,778,479 and the highest earnings forecast at $3,778,479.